Found: 23
Select item for more details and to access through your institution.
Safety and efficacy of tarenflurbil in subjects with mild Alzheimer's disease: Results from an 18-month international multi-center phase 3 trial
- Published in:
- 2009
- By:
- Publication type:
- Abstract
P4-362: Tarenflurbil clearance is not reduced in subjects with mild or moderate hepatic impairment
- Published in:
- 2008
- By:
- Publication type:
- Abstract
P4-406: Tarenflurbil (MPC-7869), a selective Aβ42-lowering agent, has no significant effect on drugs metabolized by CYP2C9
- Published in:
- 2008
- By:
- Publication type:
- Abstract
P4-395: Inhibition of CYP2C9 by fluconazole reduces clearance and increases exposure to tarenflurbil
- Published in:
- 2008
- By:
- Publication type:
- Abstract
P4-386: Exposure to tarenflurbil (MPC-7869), a selective Aβ42-lowering agent, is not affected by administration with food
- Published in:
- 2008
- By:
- Publication type:
- Abstract
P4-383: Tarenflurbil (MPC-7869), a selective Aβ42-lowering agent, has no significant effect on the pharmacokinetics and pharmacodynamics of warfarin
- Published in:
- 2008
- By:
- Publication type:
- Abstract
P4-377: Tarenflurbil a selective Aβ42-lowering agent, does not induce the metabolism of other drugs
- Published in:
- 2008
- By:
- Publication type:
- Abstract
P4-376: A phase 3 multicenter trial of tarenflurbil in subjects with mild dementia of the Alzheimer's type (Act-Earli-AD): Rationale and methodology
- Published in:
- 2008
- By:
- Publication type:
- Abstract
P4-372: Comparison of a slopes analysis using a mixed model to a traditional change from baseline analysis in an Alzheimer's disease clinical trial setting
- Published in:
- 2008
- By:
- Publication type:
- Abstract
O3-04-01: Safety and efficacy of tarenflurbil in subjects with mild Alzheimer's disease: Results from an 18-month multi-center phase 3 trial
- Published in:
- 2008
- By:
- Publication type:
- Abstract
P-015: A responder analysis of MPC-7869 (tarenflurbil), a selective Aβ42-lowering agent, in mild Alzheimer’s disease (AD): Analysis from a phase 2 study of up to 24 months of treatment
- Published in:
- 2007
- By:
- Publication type:
- Abstract
P2-411: MPC-7869 (R-flurbiprofen), a selective Ab42-lowering agent, displays no significant CYP2C9 drug-drug interactions: A phase 1 study
- Published in:
- 2006
- By:
- Publication type:
- Abstract
O4-03-08: Efficacy and safety of MPC-7869 (R-flurbiprofen), a selective Aβ42-lowering agent, in Alzheimer’s disease (AD): Results of a 12-month phase 2 trial and 1-year follow-on study
- Published in:
- 2006
- By:
- Publication type:
- Abstract
P2-411: MPC-7869 (R-flurbiprofen), a selective Ab42-lowering agent, displays no significant CYP2C9 drug-drug interactions: A phase 1 study
- Published in:
- 2006
- By:
- Publication type:
- Abstract
O4-03-08: Efficacy and safety of MPC-7869 (R-flurbiprofen), a selective Aβ42-lowering agent, in Alzheimer’s disease (AD): Results of a 12-month phase 2 trial and 1-year follow-on study
- Published in:
- 2006
- By:
- Publication type:
- Abstract
A placebo-controlled, double-blind trial of the selective AB-42 lowering agent, flurizan (MPC-7869, (R)-flurbiprofen) in patients with mild to moderate Alzheimer’s disease
- Published in:
- 2005
- By:
- Publication type:
- Abstract
Photoreactions with a fluoroquinolone antimicrobial: Evening versus morning dosing.
- Published in:
- Clinical Pharmacology & Therapeutics, 1994, v. 56, n. 5, p. 587, doi. 10.1038/clpt.1994.180
- By:
- Publication type:
- Article
Evaluation of cycloserine in the treatment of Alzheimer's disease.
- Published in:
- 1995
- By:
- Publication type:
- journal article
Effect of hemodialysis and peritoneal dialysis on aztreonam pharmacokinetics.
- Published in:
- Kidney International, 1984, v. 26, n. 3, p. 308, doi. 10.1038/ki.1984.174
- By:
- Publication type:
- Article
Effect of tarenflurbil on cognitive decline and activities of daily living in patients with mild Alzheimer disease: a randomized controlled trial.
- Published in:
- 2009
- By:
- Publication type:
- journal article
Effect of Tarenflurbil on Cognitive Decline and Activities of Daily Living in Patients With Mild Alzheimer Disease.
- Published in:
- JAMA: Journal of the American Medical Association, 2009, v. 302, n. 23, p. 2557, doi. 10.1001/jama.2009.1866
- By:
- Publication type:
- Article
Lack of cross-reactivity between aztreonam , a monobactam antibiotic, and penicillin in penicillin-allergic subjects.
- Published in:
- 1984
- By:
- Publication type:
- journal article
Renal handling of the monobactam azthreonam in healthy subjects.
- Published in:
- Clinical Pharmacology & Therapeutics, 1983, v. 33, n. 5, p. 609, doi. 10.1038/clpt.1983.82
- By:
- Publication type:
- Article